BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 22906415)

  • 1. Selective elimination of leukemia stem cells: hitting a moving target.
    Crews LA; Jamieson CH
    Cancer Lett; 2013 Sep; 338(1):15-22. PubMed ID: 22906415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic myeloid leukemia stem cells.
    Kavalerchik E; Goff D; Jamieson CH
    J Clin Oncol; 2008 Jun; 26(17):2911-5. PubMed ID: 18539972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The one-two punch: combination treatment in chronic myeloid leukemia.
    Sweet KL; Hazlehurst LA; Pinilla-Ibarz J
    Crit Rev Oncol Hematol; 2013 Dec; 88(3):667-79. PubMed ID: 23969231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
    Hu Y; Chen Y; Douglas L; Li S
    Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
    Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
    Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Acylguanidine Derivatives Targeting Smoothened Induce Antiproliferative and Pro-Apoptotic Effects in Chronic Myeloid Leukemia Cells.
    Chiarenza A; Manetti F; Petricci E; Ruat M; Naldini A; Taddei M; Carraro F
    PLoS One; 2016; 11(3):e0149919. PubMed ID: 26934052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
    Zhang B; Li M; McDonald T; Holyoake TL; Moon RT; Campana D; Shultz L; Bhatia R
    Blood; 2013 Mar; 121(10):1824-38. PubMed ID: 23299311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multifaceted mechanisms for cell survival and drug targeting in chronic myelogenous leukemia.
    Kuroda J; Shimura Y; Yamamoto-Sugitani M; Sasaki N; Taniwaki M
    Curr Cancer Drug Targets; 2013 Jan; 13(1):69-79. PubMed ID: 22414011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.
    Jin B; Wang C; Li J; Du X; Ding K; Pan J
    Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel combination treatments targeting chronic myeloid leukemia stem cells.
    Al Baghdadi T; Abonour R; Boswell HS
    Clin Lymphoma Myeloma Leuk; 2012 Apr; 12(2):94-105. PubMed ID: 22178144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukemia stem cells: the root of chronic myeloid leukemia.
    Zhou H; Xu R
    Protein Cell; 2015 Jun; 6(6):403-12. PubMed ID: 25749979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amide-linked local anesthetics preferentially target leukemia stem cell through inhibition of Wnt/β-catenin.
    Ni J; Xie T; Xiao M; Xiang W; Wang L
    Biochem Biophys Res Commun; 2018 Sep; 503(2):956-962. PubMed ID: 29932919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic myeloid leukemia stem cell biology.
    Crews LA; Jamieson CH
    Curr Hematol Malig Rep; 2012 Jun; 7(2):125-32. PubMed ID: 22467334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.
    Casetti L; Martin-Lannerée S; Najjar I; Plo I; Augé S; Roy L; Chomel JC; Lauret E; Turhan AG; Dusanter-Fourt I
    Cancer Res; 2013 Apr; 73(7):2052-8. PubMed ID: 23400594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.
    Zhao Y; Wu K; Wu Y; Melendez E; Smbatyan G; Massiello D; Kahn M
    Curr Mol Pharmacol; 2018; 11(2):113-121. PubMed ID: 28933312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting survival pathways in chronic myeloid leukaemia stem cells.
    Sinclair A; Latif AL; Holyoake TL
    Br J Pharmacol; 2013 Aug; 169(8):1693-707. PubMed ID: 23517124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin.
    Jin Y; Nie D; Li J; Du X; Lu Y; Li Y; Liu C; Zhou J; Pan J
    Clin Cancer Res; 2017 Jun; 23(11):2842-2855. PubMed ID: 27852702
    [No Abstract]   [Full Text] [Related]  

  • 18. Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.
    Shah M; Bhatia R
    Adv Exp Med Biol; 2018; 1100():97-110. PubMed ID: 30411262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia.
    Stoklosa T; Glodkowska-Mrowka E; Hoser G; Kielak M; Seferynska I; Wlodarski P
    Exp Hematol; 2013 May; 41(5):462-9. PubMed ID: 23395818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling.
    Agarwal P; Li H; Choi K; Hueneman K; He J; Welner RS; Starczynowski DT; Bhatia R
    Cell Rep; 2021 Jul; 36(2):109386. PubMed ID: 34260914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.